MCID: TCL024
MIFTS: 37

T-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for T-Cell Non-Hodgkin Lymphoma

MalaCards integrated aliases for T-Cell Non-Hodgkin Lymphoma:

Name: T-Cell Non-Hodgkin Lymphoma 59
T-Cell Nhl 59

Classifications:



External Ids:

UMLS via Orphanet 73 C0079772
Orphanet 59 ORPHA171918

Summaries for T-Cell Non-Hodgkin Lymphoma

MalaCards based summary : T-Cell Non-Hodgkin Lymphoma, also known as t-cell nhl, is related to mycosis fungoides and sarcoidosis 1. An important gene associated with T-Cell Non-Hodgkin Lymphoma is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways are CCR5 Pathway in Macrophages and IL12-mediated signaling events. The drugs Prednisone and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are cellular and hematopoietic system

Related Diseases for T-Cell Non-Hodgkin Lymphoma

Diseases in the B-Cell Non-Hodgkin Lymphoma family:

T-Cell Non-Hodgkin Lymphoma

Diseases related to T-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 mycosis fungoides 29.7 CXCR3 CCL17
2 sarcoidosis 1 29.4 CXCR3 CCL17
3 t-cell lymphoma, subcutaneous panniculitis-like 12.1
4 lymphoma, non-hodgkin, familial 11.0
5 lymphoma, hodgkin, classic 11.0
6 lymphoma 10.9
7 peripheral t-cell lymphoma 10.6
8 anaplastic large cell lymphoma 10.5
9 diffuse large b-cell lymphoma 10.4
10 b-cell lymphoma 10.4
11 angioimmunoblastic t-cell lymphoma 10.4
12 thrombophilia due to thrombin defect 10.3
13 lymphocytic leukemia 10.3
14 neutropenia 10.3
15 leukemia, chronic lymphocytic 10.2
16 immune deficiency disease 10.2
17 cutaneous t cell lymphoma 10.2
18 hard palate cancer 10.2
19 leukemia, b-cell, chronic 10.2
20 hematopoietic stem cell transplantation 10.2
21 autoimmune disease 10.1
22 burkitt lymphoma 10.1
23 breast cancer 10.1
24 kaposi sarcoma 10.1
25 ascites, chylous 10.1
26 leukemia, acute myeloid 10.1
27 leukemia, acute lymphoblastic 10.1
28 myelodysplastic syndrome 10.1
29 graft-versus-host disease 10.1
30 combined oxidative phosphorylation deficiency 12 10.1
31 exanthem 10.1
32 inflammatory bowel disease 10.1
33 mantle cell lymphoma 10.1
34 follicular lymphoma 10.1
35 lymphoblastic lymphoma 10.1
36 diphtheria 10.1
37 leukemia 10.1
38 diarrhea 10.1
39 panniculitis 10.1
40 angioedema 10.1
41 thrombocytopenia 10.1
42 pericarditis 10.1
43 myeloproliferative neoplasm 10.1
44 sagittal sinus thrombosis 10.1
45 composite lymphoma 10.1
46 breast lymphoma 10.1
47 lymphopenia 10.1
48 inflammatory breast carcinoma 10.1
49 t-cell leukemia 10.1
50 periodontitis 10.1

Graphical network of the top 20 diseases related to T-Cell Non-Hodgkin Lymphoma:



Diseases related to T-Cell Non-Hodgkin Lymphoma

Symptoms & Phenotypes for T-Cell Non-Hodgkin Lymphoma

MGI Mouse Phenotypes related to T-Cell Non-Hodgkin Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.65 B2M CCL17 CCR5 CXCR3 FBXW7
2 hematopoietic system MP:0005397 9.55 B2M CCL17 CCR5 CXCR3 FBXW7
3 immune system MP:0005387 9.35 B2M CCL17 CCR5 CXCR3 FBXW7
4 neoplasm MP:0002006 8.92 B2M CCR5 CXCR3 FBXW7

Drugs & Therapeutics for T-Cell Non-Hodgkin Lymphoma

Drugs for T-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 321)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
3
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
4
Ifosfamide Approved Phase 4 3778-73-2 3690
5
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
6
Pirarubicin Investigational Phase 4 72496-41-4
7 Thymoglobulin Phase 4
8 Tubulin Modulators Phase 4
9 Antimitotic Agents Phase 4
10
Liposomal doxorubicin Phase 4 31703
11
Isophosphamide mustard Phase 4 0
12
leucovorin Approved Phase 3 58-05-9 143 6006
13
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
14
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
15
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
16
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
17
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
18
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
21
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
22
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
23 Orange Approved Phase 3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
26
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
27
Mercaptopurine Approved Phase 3 50-44-2 667490
28
Thioguanine Approved Phase 3 154-42-7 2723601
29
Daunorubicin Approved Phase 3 20830-81-3 30323
30
Dalteparin Approved Phase 3 9005-49-6
31
Ofloxacin Approved Phase 3 82419-36-1 4583
32
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
33
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
35
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
36
Tazobactam Approved Phase 3 89786-04-9 123630
37
Piperacillin Approved Phase 3 66258-76-2 43672
38
Vancomycin Approved Phase 3 1404-90-6 441141 14969
39
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
40
Morphine Approved, Investigational Phase 3 57-27-2 5288826
41
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
42
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
43
Ribavirin Approved Phase 3 36791-04-5 37542
44
Palivizumab Approved, Investigational Phase 3 188039-54-5
45
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
46
Captopril Approved Phase 3 62571-86-2 44093
47
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
48
Acyclovir Approved Phase 3 59277-89-3 2022
49
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
50
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show top 50) (show all 260)
# Name Status NCT ID Phase Drugs
1 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
2 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
4 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Non-Hodgkin's Lymphoma T Cell Protocol Unknown status NCT00003423 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
6 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
7 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
8 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
9 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
10 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
11 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
12 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
13 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
14 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
15 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
16 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
17 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
18 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
19 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
20 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
21 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
22 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
23 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
24 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
25 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
26 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
27 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
28 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
29 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Not yet recruiting NCT04021082 Phase 2, Phase 3 Cerdulatinib
30 A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma Terminated NCT01098656 Phase 3 lenalidomide
31 Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
32 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
33 Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study. Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
34 PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
35 A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
36 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
37 Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL Unknown status NCT01016990 Phase 2 valproic acid
38 Phase II Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia and Blast Crisis of Chronic Myeloid Leukemia Unknown status NCT00003885 Phase 2 arsenic trioxide
39 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
40 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
41 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
42 Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome Completed NCT00057967 Phase 2
43 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
44 PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA Completed NCT00002635 Phase 2 aminocamptothecin
45 Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome Completed NCT00002479 Phase 2 tretinoin
46 Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil®) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin®) Completed NCT00255801 Phase 2 Targretin® (bexarotene);pegylated liposomal doxorubicin hydrochloride
47 A Phase II Study of Bortezomib (VELCADE®) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00182637 Phase 2 bortezomib
48 Phase II Trial Of Oral Bexarotene (Targretin) Combined With Interferon Alfa-2b (Intron-A) For Patients With Cutaneous T-Cell Lymphoma Completed NCT00030849 Phase 2 bexarotene
49 Phase 1-2 Multi-Center Study of Intravenous BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00061880 Phase 1, Phase 2 forodesine hydrochloride
50 A Phase II Study of Gemcitabine and Bexarotene (Gembex) in the Treatment of Cutaneous T-cell Lymphoma Completed NCT00660231 Phase 2 bexarotene;gemcitabine hydrochloride

Search NIH Clinical Center for T-Cell Non-Hodgkin Lymphoma

Genetic Tests for T-Cell Non-Hodgkin Lymphoma

Anatomical Context for T-Cell Non-Hodgkin Lymphoma

MalaCards organs/tissues related to T-Cell Non-Hodgkin Lymphoma:

41
T Cells, Bone, Bone Marrow, B Cells, Liver, Myeloid, Nk Cells

Publications for T-Cell Non-Hodgkin Lymphoma

Articles related to T-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 358)
# Title Authors PMID Year
1
Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma. 38
31072226 2019
2
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) associated with or without lymphoma: Comparison of clinical features and risk factors suggestive of underlying lymphomas. 38
31088767 2019
3
Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies. 38
31229161 2019
4
Beneficial effect of consolidative radiotherapy for patients with lymphoma and skeletal involvement. 38
31374054 2019
5
Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma. 38
31229154 2019
6
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. 38
30628511 2019
7
Cytological features of breast implant-associated anaplastic large cell lymphoma in pleural effusion. 38
31348611 2019
8
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. 38
31400706 2019
9
From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK. 38
30681723 2019
10
A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. 38
30547695 2019
11
The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma. 38
31017033 2019
12
Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group. 38
30940492 2019
13
Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement. 38
30471148 2019
14
Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). 38
30715169 2019
15
Transplantation. 38
30596223 2019
16
90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma. 38
30820474 2019
17
How I treat breast implant-associated anaplastic large cell lymphoma. 38
30209119 2018
18
Peripheral T-cell non-Hodgkin lymphoma manifesting as a primary lesion on the lip: A rare case report. 38
30289179 2018
19
A prospective analysis of circulating saturated and monounsaturated fatty acids and risk of non-Hodgkin lymphoma. 38
29756258 2018
20
Adult onset haemophagocytic lymphohistiocytosis prognosis is affected by underlying disease: analysis of a single-institution series of 174 patients. 38
30378643 2018
21
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas. 38
30231561 2018
22
Epidemiology and prognostic indicators in laryngeal lymphoma: A population-based analysis. 38
29392765 2018
23
Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies. 38
29532605 2018
24
Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma. 38
29859415 2018
25
A 54-year-old male with diabetic nephropathy and suspected disseminated tuberculosis: Clinicopathologic correlation in a rare diagnosis. 38
30004060 2018
26
Breast necrosis in a patient with primary T-cell non-Hodgkin lymphoma. 38
29452969 2018
27
Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. 38
28972423 2018
28
A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. 38
29438091 2018
29
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. 38
29475723 2018
30
Aggressive Angioimmunoblastic T Cell Lymphomas (AITL) with Soft Tissue Extranodal Mass Varied Histopathological Patterns with Peripheral Blood, Bone Marrow, and Splenic Involvement and Review of Literature. 38
29563728 2018
31
Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature. 38
29269521 2018
32
Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy. 38
29515769 2018
33
Cardiac Hematological Malignancies: Typical Growth Patterns, Imaging Features, and Clinical Outcome. 38
28602141 2018
34
Alteration of gene expression profile in CD3+ T-cells after downregulating MALT1. 38
30538965 2018
35
Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma. 38
29689086 2018
36
Eosinophilic infiltrate resembling eosinophilic cellulitis (Wells syndrome) in a patient with mycosis fungoides. 38
29469767 2018
37
T-cell lymphoma of oral cavity: A rare entity. 38
29731565 2018
38
Blueprint unknown: a case for multidisciplinary management of advanced penile mycosis fungoides. 38
29260643 2017
39
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. 38
28822981 2017
40
Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy. 38
29245981 2017
41
Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue. 38
28290723 2017
42
Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. 38
28822058 2017
43
Occupational ultraviolet exposure and risk of non-Hodgkin's lymphomas: a meta-analysis. 38
28977951 2017
44
Myxoid variant of primary cutaneous anaplastic large cell lymphoma: First 2 cases. 38
28626950 2017
45
Coffee consumption and risk of non-Hodgkin's lymphoma: evidence from the Italian multicentre case-control study. 38
28612129 2017
46
Demodicosis in Pediatric Cancer. 38
28486260 2017
47
Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis. 38
28660145 2017
48
Immunoglobulin heavy and light chains and T-cell receptor beta and gamma chains PCR assessment on cytological samples. A study comparing FTA cards and cryopreserved lymph node fine-needle cytology. 38
28008668 2017
49
Epidemiology of Nasopharyngeal Lymphoma in the United States: A Population-Based Analysis of 1119 Cases. 38
28322119 2017
50
Four Lymphomas in 1 Patient: A Unique Case of Triple Composite Non-Hodgkin Lymphoma Followed by Classical Hodgkin Lymphoma. 38
27688525 2017

Variations for T-Cell Non-Hodgkin Lymphoma

Expression for T-Cell Non-Hodgkin Lymphoma

Search GEO for disease gene expression data for T-Cell Non-Hodgkin Lymphoma.

Pathways for T-Cell Non-Hodgkin Lymphoma

GO Terms for T-Cell Non-Hodgkin Lymphoma

Cellular components related to T-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.13 CXCR3 CCR5 B2M
2 external side of plasma membrane GO:0009897 8.8 CXCR3 CCR5 B2M

Biological processes related to T-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.43 CXCR3 CCR5 CCL17
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.4 CXCR3 CCR5
3 cell chemotaxis GO:0060326 9.37 CXCR3 CCR5
4 chemotaxis GO:0006935 9.33 CXCR3 CCR5 CCL17
5 calcium-mediated signaling GO:0019722 9.32 CXCR3 CCR5
6 immune response GO:0006955 9.26 CXCR3 CCR5 CCL17 B2M
7 chemokine-mediated signaling pathway GO:0070098 8.8 CXCR3 CCR5 CCL17

Molecular functions related to T-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine binding GO:0019956 9.26 CXCR3 CCR5
2 C-C chemokine binding GO:0019957 9.16 CXCR3 CCR5
3 C-C chemokine receptor activity GO:0016493 8.96 CXCR3 CCR5
4 chemokine receptor activity GO:0004950 8.62 CXCR3 CCR5

Sources for T-Cell Non-Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....